Fig. 2

The silencing of SHP1 and SHP2 specifically enhances HEL cell differentiation. a) Downregulation of SHP1 with the RNAi sequences employed. b) Levels of CD41 and CD61 surface markers in SHP1-silenced cells untreated and stimulated with 20 nM PMA for 48 h. c) Downregulation of SHP2 with the RNAi sequences employed. d) Levels of CD41 and CD61 surface markers in SHP2-silenced cells untreated and stimulated for differentiation with 20 nM PMA for 48 h. e) Flow cytometry analysis of DNA content SHP1-silenced cells after 7 days of 20 nM PMA treatment. f) Flow cytometry analysis of DNA content SHP2-silenced cells after 7 days of 20 nM PMA treatment. g) Downregulation of PTP1B with the RNAi sequences employed. h) Levels of CD41 and CD61 surface markers in PTP1B-silenced cells untreated and stimulated for differentiation with 20 nM PMA for 48 h. All comparisons were made against control RNAi